sitagliptin and metformin hydrochloride

FDA Drug Profile — Sitagliptin and Metformin Hydrochloride, JANUMET XR, ZITUVIMET XR

Drug Details

Generic Name
sitagliptin and metformin hydrochloride
Brand Names
Sitagliptin and Metformin Hydrochloride, JANUMET XR, ZITUVIMET XR
Application Number
NDA216778
Sponsor
Zydus Lifesciences Limited
NDC Codes
16
Dosage Forms
TABLET, FILM COATED, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
METFORMIN HYDROCHLORIDE, SITAGLIPTIN, SITAGLIPTIN PHOSPHATE

Indications and Usage

1 INDICATIONS AND USAGE JANUMET ® XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUMET XR is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not for the treatment of type 1 diabetes. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 , 5.2 ) Limitations of Use JANUMET XR should not be used in patients with type 1 diabetes mellitus. JANUMET XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET XR. [See Warnings and Precautions (5.2) .]